HOME >> MEDICINE >> NEWS
Antiplatelet drug found to reduce risk of recurrent heart attacks and stroke is cost-effective

ORLANDO -- The antiplatelet medicine clopidogrel is not only effective in reducing the risk of recurrent heart attack and stroke, it is also extremely cost-effective, according to data presented today by researchers from Emory University at the American Heart Association's Scientific Sessions.

"We have three separate investigations showing uniform results in both the short and long-term use of clopidogrel. Specifically, the use of clopidogrel in addition to aspirin produces a significant risk reduction in recurrent heart attack, stroke or cardiovascular death," says William Weintraub, M.D. FACC, Director, Emory Center for Outcomes Research in the Division of Cardiology, Department of Medicine, Emory University School of Medicine, who presented the data. "The study findings and the cost-effectiveness data suggest that at least one year of therapy with clopidogrel is an attractive value. In fact, we believe it should be the standard of care for this patient population."

The Emory University investigators analyzed the drug's cost-effectiveness ratio in two major clinical studies -- the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial and the CREDO (Clopidogrel for the Reduction of Events During Observation) trial -- as well as a substudy of CURE, called PCI-CURE . Cost-effectiveness ratio is the incremental cost of using an intervention to obtain a unit of effectiveness (such as dollars per life-year gained) compared to another treatment or no treatment.

Based on CURE, the Emory researchers found that the cost-effectiveness ratio was $6,173 per life year gained. PCI-CURE, which evaluated people who received clopidogrel for up to one year after having an angioplasty or stent, demonstrated a cost-effectiveness ratio of $5,910 per life year gained. In CREDO, patients were given a dose of clopidogrel before having an angioplasty or stenting procedures and continued on clopidogrel therapy for up to one year. The cost-effect
'"/>

Contact: Sherry Baker
emoryheartnews@aol.com
404-377-1398
Emory University Health Sciences Center
12-Nov-2003


Page: 1 2

Related medicine news :

1. Antiplatelet drugs: comparison of clopidogrel with aspirin
2. Acupuncture found to lower elevations in blood pressure
3. Proteins found in urine of pregnant women could help diagnose preeclampsia
4. Potential drug target for treating cocaine abuse found
5. Similar results found in both older and younger patients undergoing weight-loss surgery
6. Infectious agent linked to mad cow disease found in organs other than the brain
7. Generation gap found in chronic pain
8. A site for sore eyes: New target for allergies found under the eyelid
9. Chemicals found in cherries may help fight diabetes
10. Thanks for the memories: cinematic portrayal of amnesia is profoundly misleading
11. Very high prevalence of virus linked to cervical cancer found in adolescent women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2017)... ... ... The February 13, 2017, assassination of Kim Jong-nam, the half brother of North ... use of chemical weapons. Many questions exist about the effect that nerve agents can ... , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical Institute, and one of the United ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... distribution in North America, today announced it would be offering some it’s exclusive ... prides itself on crafting quality and unique baby clothing/feeding products, will team up ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... and reporting for healthcare organizations. This comprehensive and customizable solution empowers StaffBridge ... StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting data, ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports ... a study released today at the 1st Pan American Parkinson’s and Movement Disorders ... be effective in improving cognitive function in PD patients. This study, led by ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017 Leading Countries, Technologies and Companies ... to grow at a CAGR of 8.9% from 2016-2021 and CAGR ... a CAGR of 9.1% from 2016 to 2027. The market is ... ... you Read on to discover how you can exploit the ...
(Date:2/24/2017)... , Feb. 24, 2017  Today, exocad America ... labs have a new path to produce 510(K) ... Biodenta implant library integrated into exocad DentalCAD software. ... FDA compliant Good Manufacturing Processes (GMP,s) into their ... Biodenta, and complete an audit process. Then, dental labs ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of the ... their offering. ... research Hemophilia Drugs Price Analysis and Strategies - 2016, provides drug pricing ... the following questions: What are the key ... in the Global Hemophilia market? What are the unit ...
Breaking Medicine Technology:
Cached News: